Last-Resort drug made available for lymphoma patients
NCT ID NCT05619367
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This program provides compassionate use of odronextamab for people with relapsed or refractory follicular lymphoma, diffuse large B-cell lymphoma, or other B-cell non-Hodgkin lymphomas who have no other treatment options. Odronextamab is a drug that helps the immune system attack cancer cells. The goal is to offer a potential treatment when standard therapies are no longer working.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- odronextamab (a drug that helps the immune system attack cancer cells)
- What this could lead to
- If it works, this could provide a treatment option for patients with certain lymphomas who have run out of standard therapies.
- What could go wrong
- This is a compassionate use program, not a formal trial, so results are not systematically collected. It may not work for everyone and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA (NHL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Can a single shot build a cancer army inside the body?
- Can a smart immune cell with a kill switch beat tough lymphomas?
- Ultra-Fast CAR-T cells aim to beat back tough lymphomas
- New drug combo aims to boost lymphoma treatment